Cytosorbents (CTSO) Scheduled to Post Quarterly Earnings on Thursday

Cytosorbents (NASDAQ:CTSO) will post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Cytosorbents to post earnings of ($0.12) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Thursday, March 14th. The medical research company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.02. The business had revenue of $8.67 million during the quarter, compared to analysts’ expectations of $9.29 million. Cytosorbents had a negative net margin of 78.43% and a negative return on equity of 120.24%. On average, analysts expect Cytosorbents to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytosorbents Stock Up 5.7 %

Cytosorbents stock opened at $0.93 on Tuesday. Cytosorbents has a twelve month low of $0.78 and a twelve month high of $4.29. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.51 and a current ratio of 1.77. The firm has a market cap of $50.51 million, a PE ratio of -1.45 and a beta of 0.62. The firm’s 50 day moving average price is $0.91 and its two-hundred day moving average price is $1.12.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CTSO. StockNews.com started coverage on shares of Cytosorbents in a research note on Thursday, May 2nd. They issued a “hold” rating on the stock. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research report on Tuesday.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.